venetoclax

A BCL-2 inhibitor with antineoplastic activity that is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA associated with chromosome 17p deletion; structure in first source.

Also Known As:

4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide; ABT-199; GDC-0199; RG-7601; RG7601; Venclexta; benzamide, 4-(4-((2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl)methyl)-1-piperazinyl)-n-((3-nitro-4-(((tetrahydro-2h-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-2-(1h-pyrrolo(2,3-b)pyridin-5-yloxy)-

Networked: 1653 relevant articles (259 outcomes, 259 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Konopleva, Marina: 50 articles (05/2022 - 03/2014)
2.	DiNardo, Courtney D: 45 articles (12/2022 - 10/2016)
3.	Salem, Ahmed Hamed: 42 articles (08/2022 - 01/2016)
4.	Seymour, John F: 41 articles (11/2022 - 02/2013)
5.	Roberts, Andrew W: 39 articles (11/2022 - 02/2013)
6.	Davids, Matthew S: 35 articles (01/2022 - 02/2013)
7.	Ravandi, Farhad: 30 articles (11/2022 - 01/2018)
8.	Kantarjian, Hagop M: 29 articles (11/2022 - 12/2015)
9.	Borthakur, Gautam: 27 articles (11/2022 - 03/2014)
10.	Pemmaraju, Naveen: 26 articles (11/2022 - 01/2017)

Related Diseases

1.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/01/2023 - "Venetoclax is a potent inhibitor that specifically targets B-cell lymphoma-2 (BCL-2), which has been demonstrated to be effective in preclinical studies utilizing acute myeloid leukemia (AML) cell lines and xenograft models. " 10/24/2023 - "Combinations with other drugs as first-line treatment has to date not proven more efficacious than monotherapy, although combinations approved for acute myeloid leukemia, including venetoclax currently are under evaluation and often used as rescue treatment. " 01/01/2022 - "The addition of Venetoclax (VEN) to Hypomethylating agents (HMAs) significantly improves the probability of complete remission and prolongs survival in patients with Acute Myeloid Leukemia (AML) when compared to HMA alone. " 03/13/2023 - "Recently, we described the superior therapeutic efficacy of a novel HMA, namely, NTX-301, when used as a monotherapy and in combination with venetoclax in the treatment of acute myeloid leukemia. " 01/01/2023 - "Venetoclax-based combinations (including those with hypomethylating agents) were able to improve outcomes for older patients with acute myeloid leukemia, including both remission rates and overall survival. "
2.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 03/18/2023 - "The oral, highly selective Bcl2 inhibitor venetoclax has substantially improved the therapeutic landscape of chronic lymphocytic leukemia (CLL). " 01/01/2023 - "The primary endpoint was complete response or remission (including with incomplete marrow recovery), assessed by independent review according to the 2018 International Workshop on Chronic Lymphocytic Leukemia criteria, in efficacy-evaluable patients with previous BTK inhibitor progression and venetoclax failure (the primary efficacy analysis set) at DL2 (null hypothesis of ≤5%). " 01/01/2020 - "Whether BTK inhibitors are effective when used after venetoclax in patients with chronic lymphocytic leukemia is an important unanswered question. " 01/01/2019 - "The BCL2 inhibitor venetoclax induces high rates of durable remission in patients with previously treated chronic lymphocytic leukemia (CLL). " 05/01/2022 - "Venetoclax alone or in combination with other regimens treatment achieve deep and sustained remission of relapsed/refractory chronic lymphocytic leukemia: a meta-analysis."
3.	Neoplasms (Cancer) 01/01/2020 - "These data indicate that CDK9 inhibitors could be highly efficacious in tumors that depend on MCL-1 for survival or when used in combination with venetoclax in malignancies dependent on MCL-1 and BCL-2." 04/01/2022 - "We present a case of a 27-year-old male patient diagnosed with blastic plasmacytoid dendritic cell neoplasm with unusual CNS manifestations and without skin involvement who achieved complete remission with venetoclax and improvement of neurological symptoms, making him a candidate for hematopoietic stem cell transplant." 05/01/2017 - "Venetoclax has demonstrated efficacy in multiple subtypes of lymphoid malignancies, including patients with relapsed/refractory CLL harboring deletion 17p, with an overall response rate of nearly 80%. " 05/01/2017 - "Venetoclax has demonstrated promising results in relapsed/refractory lymphoid malignancies, with an acceptable adverse effect profile. " 01/01/2018 - "Furthermore, encouraging preclinical studies of BH3 mimetics that target other BCL-2 pro-survival members, particularly MCL-1, offer promise for cancers resistant to venetoclax. "
4.	Leukemia 11/01/2022 - "Among patients treated with targeted agents after venetoclax, the overall response rate (ORR; composite of complete remission [CR]/CR with incomplete count recovery, partial remission, and morphologic leukemia free state) was 17.7 % (n = 9 patients) and median OS of 4.2 months. " 05/01/2020 - "The development of new targeted drugs (Hylteritinib, Venetoclax) significantly improved the survival of patients, but resistance, as well as cytotoxic anti-leukemia drugs, often occurs. " 11/01/2019 - "The characteristic high-level expression of BCL2 in CLL that can enhance leukemia-cell survival has now become an Achilles heel targeted by clinically effective drugs such as venetoclax. " 01/01/2019 - "The unexpected efficacy of ABT-199 observed in hypodiploid leukemias lacking BIM expression (the major reported mediator of ABT-199-induced apoptosis) led us to investigate the mechanism of action of ABT-199 in the absence of BIM. " 12/01/2023 - "Venetoclax and TKI-based combination regimens may be a feasible approach for Ph + leukemias, and prospective studies are needed to properly assess the safety, tolerability and efficacy of this regimen."
5.	Hematologic Neoplasms (Hematological Malignancy) 01/01/2023 - "The new gold standard for elderly and frail patients not able to undergo intensive treatment regimens in AML is the combination of hypomethylating agents with venetoclax, a BCL-2 inhibitor that also showed excellent treatment outcomes in other hematological malignancies. " 01/01/2018 - "Venetoclax (ABT-199) is a Bcl-2-specific BH3-mimetic that has shown significant promise in certain subtypes of CLL as well as in several other hematologic malignancies. " 11/15/2015 - "Here, we discuss the biology of the intrinsic pathway of apoptosis, an assay known as BH3 profiling that can interrogate this pathway, early attempts to target BCL-2 clinically, and the recent promising results with the BCL-2 antagonist venetoclax (ABT-199) in clinical trials in hematologic malignancies. " 04/03/2018 - "Since selective BCL-2 inhibition is a promising treatment strategy in hematologic malignancies, we tested the therapeutic impact of ABT-199 on MDS patient samples bearing an adverse mutational profile. " 01/01/2020 - "A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies."

Related Drugs and Biologics

1.	Azacitidine (5 Azacytidine)
2.	ibrutinib
3.	Decitabine
4.	Cytarabine (Cytosar-U)
5.	obinutuzumab
6.	Rituximab (Mabthera)
7.	Agammaglobulinaemia Tyrosine Kinase
8.	Proteins (Proteins, Gene)
9.	idelalisib
10.	navitoclax

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Hematopoietic Stem Cell Transplantation
4.	Induction Chemotherapy
5.	Salvage Therapy